ANO1 and cancer: Collectively, our work proved that the amplification/upregulation of ANO1 in GI cancers abolishes cancer ferroptosis in a PI3K‐Akt signaling‐dependent manner, consequently increases cancer cell survival and strengthens CAF recruitment through elevating TGF‐β release, and thus promotes tumor progression and cripples anti‐tumor immune responses, generating resistance to immunotherapy.